Novo Nordisk Share Holder Equity 2010-2024 | NVO

Novo Nordisk share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Novo Nordisk share holder equity for the quarter ending March 31, 2024 was $14.401B, a 25.12% increase year-over-year.
  • Novo Nordisk share holder equity for 2023 was $15.473B, a 30.88% increase from 2022.
  • Novo Nordisk share holder equity for 2022 was $11.822B, a 5.03% increase from 2021.
  • Novo Nordisk share holder equity for 2021 was $11.256B, a 16.02% increase from 2020.
Novo Nordisk Annual Share Holder Equity
(Millions of US $)
2023 $15,473
2022 $11,822
2021 $11,256
2020 $9,701
2019 $8,633
2018 $7,926
2017 $7,567
2016 $6,727
2015 $6,989
2014 $7,184
2013 $7,582
2012 $7,021
2011 $6,999
2010 $6,591
2009 $6,693
Novo Nordisk Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $14,401
2023-12-31 $15,473
2023-09-30 $13,577
2023-06-30 $13,218
2023-03-31 $11,510
2022-12-31 $11,822
2022-09-30 $10,375
2022-06-30 $10,647
2022-03-31 $10,036
2021-12-31 $11,256
2021-09-30 $10,485
2021-06-30 $10,627
2021-03-31 $9,482
2020-12-31 $9,701
2020-09-30 $9,353
2020-06-30 $8,870
2020-03-31 $8,035
2019-12-31 $8,633
2019-09-30 $7,890
2019-06-30 $7,995
2019-03-31 $7,202
2018-12-31 $7,926
2018-09-30 $7,412
2018-06-30 $7,858
2018-03-31 $7,304
2017-12-31 $7,567
2017-09-30 $7,417
2017-06-30 $7,164
2017-03-31 $5,779
2016-12-31 $6,727
2016-09-30 $6,199
2016-06-30 $6,469
2016-03-31 $5,514
2015-12-31 $6,989
2015-09-30 $6,428
2015-06-30 $5,796
2015-03-31 $4,868
2014-12-31 $7,184
2014-09-30 $6,758
2014-06-30 $6,738
2014-03-31 $6,169
2013-12-31 $7,582
2013-09-30 $6,949
2013-06-30 $6,195
2013-03-31 $5,986
2012-12-31 $7,021
2012-09-30 $5,994
2012-06-30 $5,415
2012-03-31 $5,705
2011-12-31 $6,999
2011-09-30 $6,731
2011-06-30 $7,134
2011-03-31 $6,376
2010-12-31 $6,591
2010-09-30 $5,928
2010-06-30 $5,752
2010-03-31 $6,122
2009-12-31 $6,693
2009-09-30 $6,696
2009-06-30 $6,234
2009-03-31 $5,485
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $631.845B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11